The research group Disease and Intervention Dynamics focuses on developing and using mathematical models to understand parasite, host and intervention dynamics. The main aim is to generate evidence for decision-making along the whole pathway of new tool development, from preclinical to clinical testing, and at implementation in real populations and health systems. The model-based evidences ensure efficient selection of optimal drugs and vaccines to achieve disease burden reduction and elimination.

Our Main Emphasis

In particular, we investigate pharmacokinetic and pharmacodynamics at pre-clinical and clinical level for new drugs to treat malaria and helminths. We collaborate with the University Hospital Basel on understanding drug-drug interactions for HIV drugs.  We assess new malaria vaccines at clinical and implementation level. And we use data and models to explore most effective, cost-effective and equitable delivery of current and new malaria interventions.

Melissa Penny

Melissa Penny, SNF Professor, PhD, PD

Camponovo F, Ockenhouse C. F, Lee C, Penny M. A. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study. BMC Infect Dis. 2019;19:920. DOI: 10.1186/s12879-019-4467-4

Dietler D et al. Health in the 2030 agenda for sustainable development: from framework to action, transforming challenges into opportunities. J Glob Health. 2019;9(2):020201. DOI: 10.7189/jogh.09.020201

Lee T.E, Penny M.A. Identifying key factors of the transmission dynamics of drug-resistant malaria. J Theor Biol. 2019;462:210-220. DOI: 10.1016/j.jtbi.2018.10.050

Meister I et al. Pooled population pharmacokinetic analysis of tribendimidine for the treatment of Opisthorchis viverrini infections. Antimicrob Agents Chemother. 2019;63(4):e01391-18. DOI: 10.1128/AAC.01391-18

Stader F, Kinvig H, Penny M.A, Battegay M, Siccardi M, Marzolini C. Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving drug exposure changes in the elderly. Clin Pharmacokinet. 2019(in press). DOI: 10.1007/s40262-019-00822-9

Group | Disease and Intervention Dynamics